The online version of this article (doi:10.1186/s12905-017-0370-6) contains supplementary material, which is available to authorized users.
It is unclear if the use of hormone therapy (HT) in carriers of BRCA mutations improves the quality of life (QOL) without increasing the risk of breast cancer following a risk-reducing salpingo-oophorectomy (RRSO). Our objective was to assess the effect of HT on QOL and breast cancer risk, after RRSO.
We searched MEDLINE, EMBASE, CINHAL, and others, from inception to July 22, 2016, to identify relevant studies. Two reviewers independently screened identified records for controlled trials and observational studies that addressed the effect of HT on QOL and breast cancer risk in women with BRCA mutations, post RRSO. Two reviewers independently extracted data on populations, interventions, comparators, outcomes, and methodological quality. Studies addressing the same outcome were synthesized using written evidence summaries or tables.
Of the 1,059 records identified, 13 met our inclusion criteria. All studies were observational. Six studies assessed the effect on QOL. Of these, 3 showed improvement in QOL with HT use. The risk of breast cancer was evaluated in 4 studies. The mean duration of follow-up was 2.6 years (range 0.1-19.1). The risk of breast cancer did not change with HT use in all 4 studies.
Cumulative evidence from our review suggests that short-term HT use following RRSO improves QOL. The effect on breast cancer risk is still unclear. There are too few long-term studies to draw any strong conclusions. The need for future well-designed RCTs for more established evidence is imperative.
Additional file 1: A Search Strategy for Electronic Bibliographic Databases. The document provides a detailed account of the search strategy implemented by an expert searcher (SC) in a variety of electronic databases including MEDLINE, EMBASE, CINAHL, Proquest Dissertations and Theses, SCOPUS, LILACS, PsycINFO, and Cochrane Library. The search was initially performed in February/March 2014 and updated in March 2016. (DOCX 354 kb)12905_2017_370_MOESM1_ESM.docx
Additional file 2: A Search Strategy for Grey Literature: An Update. The document provides an update of the grey literature search performed in July, 2016, on SCOPUS, Proquest Dissertations and Theses, Clinical trial registries, Web of Science, and Google Scholar. (DOCX 22 kb)12905_2017_370_MOESM2_ESM.docx
Additional file 3: The Effect of Hormone Therapy on Quality of Life and Breast Cancer Risk After Risk-Reducing Salpingo-oophorectomy: Meta-analyses of Pooled studies. The document provides a written description of the methods and the results of the meta-analyses conducted in our study. (DOCX 39 kb)12905_2017_370_MOESM3_ESM.docx
Additional file 4: The results of full-text screening of eligible articles and the reason for exclusion whenever this may apply. (DOCX 19 kb)12905_2017_370_MOESM4_ESM.docx
Additional file 5: A Checklist summarizing compliance with MOOSE guidelines. The attached document is a checklist highlighting the compliance of our systematic review with the quality criteria specified by MOOSE guidelines. (DOC 27 kb)12905_2017_370_MOESM5_ESM.doc
Brohet RM, Velthuizen ME, Hogervorst FB, Meijers-Heijboer HE, Seynaeve C, Collee MJ, Verhoef S, Ausems MG, Hoogerbrugge N, van Asperen CJ, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. 2014;51(2):98–107. CrossRefPubMed
Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109:1. CrossRef
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collee JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107:5.
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016;27 suppl 5:v103–10. CrossRefPubMed
Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153–62. PubMed
Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8(5):562–94. PubMed
Gass ML, Heights M, Manson JE, Cosman F, Hayes H, Grodstein F, Lab C, Jordan V, Karas RH, Kaunitz AM, Maki PM, Schmidt PJ, Shifren JL, Stuenkel CA, Utian WH, Wisch KJ, Bilancini AM, Clarkson TB, Gass ML, Heights M, Goldstein SR, Kagan R, Kaunitz AM, Maki PM, Manson JE, Pace DT, Schiff I, Meigs JV, Obstetrics V, Schnatz PF, Shapiro M, Shifren JL, Obstetrics V, Sievert LL, Utian WH, Warren MP. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257–71.
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–68. CrossRefPubMed
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, Van’t V, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804–10. CrossRefPubMed
Birrer N, Chinchilla C, Del Carmen M, Dizon DS. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature. Am J Clin Oncol. 2016. doi: 10.1097/COC.0000000000000269.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12. CrossRefPubMed
Nolan JP, Hazinski MF, Billi JE, Boettiger BW, Bossaert L, de Caen AR, Deakin CD, Drajer S, Eigel B, Hickey RW, et al. Part 1: Executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation. 2010;2010(81 Suppl 1):e1–25. CrossRef
Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer. 2011;105(1):22–7. CrossRefPubMedPubMedCentral
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006;24(22):3576–82. CrossRefPubMed
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23(28):6890–8. CrossRefPubMed
Kotz K, Alexander JL, Dennerstein L. Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women. J Womens Health (Larchmt). 2006;15(8):898–908. CrossRef
Buzgova R, Kaniokova J. The influence of hormone replacement therapy on the quality of life of women in menopause. Ceska Gynekol. 2013;78(5):420–6. PubMed
Zimmerman VL, Smeltzer SC. Hormone therapy and breast cancer. Clin Excell Nurse Pract. 2000;4(1):30–4. PubMed
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. CrossRefPubMed
Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric. 2016;1–4.
Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4, CD002978.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500.
Dennerstein L, Alexander JL, Kotz K. The menopause and sexual functioning: a review of the population-based studies. Annu Rev Sex Res. 2003;14:64–82. PubMed
Higgins JPT, Green S. Cochrane Collaboration.: Cochrane handbook for systematic reviews of interventions. Chichester, England. Hoboken: Wiley-Blackwell; 2008. CrossRef
- The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review
Dean T. Eurich
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II